FGFR2 and intrahepatic cholangiocarcinoma: In a multicenter, phase 1–2 study (NCT01752920), 29 FGFR2 fusion-positive inoperable intrahepatic cholangiocarcinoma patients were treated with derazantinib, another pan-FGFR inhibitor, with promising anti-tumor activity and safety profile, although the fusion partners of FGFR2 have not been clearly demonstrated [31].